http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#Head http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#assertion http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#provenance http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#pubinfo http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#assertion http://purl.obolibrary.org/obo/DOID_5409 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_5409 http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01030 http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#association http://www.w3.org/2000/01/rdf-schema#label topotecan hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy as a single agent 1 1 patients with small cell lung cancer slsc platinum sensitive disease who progressed at least 6 days after initiation of first line chemotherapy as a single agent 1 2 patients with stage iv b recurrent or persistent cervical cancer which is not amenable to curative treatment in combination with cisplatin 1 3 topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy topotecan hydrochloride for injection as a single agent is indicated for the treatment of patients with small cell lung cancer sclc with platinum sensitive disease who progressed at least 6 days after initiation of first line chemotherapy topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of patients with stage iv b recurrent or persistent cervical cancer of the cervix not amenable to curative treatment http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01030 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#provenance http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#pubinfo http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#sig http://purl.org/nanopub/x/hasSignature bPZb3rbfpMtx759fXYChFAo20PcPB3FYMAQQi/ecynWMhwYhaSvKZJE66I9I4E7nJVeIL6fAkH3jESQ4JLf/UD3ZTO/FygaPhsrwanhf72lJERw19+YaMR90P1itKqJN+B/QWGHHn8B5v/dyOadiTuXQY/DgjCwct2NecVGJtKA= http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM http://purl.org/dc/terms/created 2021-07-03T13:18:18.294+02:00 http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAvuKhEHk8bx-SNHDVQ5u9RYo3VmNpxdu6DYjRGgc3QMM https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs